Related Experiment Video
Updated: Mar 2, 2026
Porcine Corneal Tissue Explant to Study the Efficacy of Herpes Simplex Virus-1 Antivirals
Published on: September 20, 2021
[How I treat… a neonatal Herpes simplex virus infection]
Insights
Neonatal herpes simplex virus (HSV) infection, though rare, poses significant risks. Early diagnosis and a six-month course of oral aciclovir treatment are crucial for improving infant outcomes and preventing severe sequelae.
Area of Science:
- Neonatal Medicine
- Virology
- Infectious Diseases
Background:
- Neonatal herpes simplex virus (HSV) infection is a rare but serious condition with a high risk of mortality and long-term neurological complications.
- Accurate diagnosis relies on specific clinical presentations and biological testing.
Purpose of the Study:
- To review the literature on neonatal HSV infection management.
- To highlight the importance of early diagnosis and appropriate treatment strategies.
- To emphasize the benefits of prolonged antiviral therapy for improved prognosis.
Main Methods:
- Literature review based on a clinical case of neonatal HSV infection.
- Analysis of diagnostic criteria and treatment protocols for neonatal HSV.
- Evaluation of the efficacy of aciclovir in treating neonatal HSV.
Main Results:
- Aciclovir is the primary treatment for neonatal HSV infection.
- Treatment duration varies based on disease severity.
- A six-month suppressiv e-dose oral aciclovir regimen is recommended for better outcomes.
Conclusions:
- Prompt diagnosis and timely initiation of antiviral therapy are critical for managing neonatal HSV.
- Extended suppressiv e aciclovir treatment can significantly improve the long-term prognosis for affected infants.
- Optimizing management strategies can reduce the severe sequelae associated with neonatal herpes simplex virus infection.
Abstract:
Neonatal herpes simplex virus infection is rare but important to recognize because of the major risk of sequelae or death. The diagnosis is mainly based on specific clinical and biological analyses. Aciclovir is the treatment of choice, duration of administration depending on the severity of the disease. A six-month treatment with suppressive-dose oral aciclovir is recommended to improve the child's prognosis. From a clinical case, we reviewed the literature to improve the management.
